Gülşah ELBÜKEN, Bahadir YAZİCİOGLU, Onur ÖZTÜRK, MEHMET DERYA DEMİRAĞ

A Rare Cause of Hypercalcemia: “Immobilization”. A Case Report and Literature Review

Immobilization hypercalcemia (IH) mainly results from rapid bone turnover and may be seen after spinal cord injury or long bone fracture in particular in children and adolescents. The pathophysiology of this entity is entirely unknown. A-19 year-old, male quadriplegic adolescent was referred to our outpatient clinic by a family physician. At presentation he had some vague symptoms due to hypercalcemia including fatigue, nausea, vomiting, anorexia, constipation and dehydration. Laboratory investigations for hypercalcemia revealed low intact parathyroid hormone level, low 25-0H vitamin D, and high 24-hour urine calcium. He was diagnosed as having IH after all other causes of hypercalcemia were excluded. The pathophysiology of IH remains unclear. Treatment is directed towards lowering the serum calcium level. Up to date, intravenous hydration with isotonic saline, furosemide and salmon calcitonin have been the conventional therapies. Other treatment options include bisposphonates (such as etidronate, zoledronate or pamidronate) or, an inhibitor of receptor activator of nuclear factor kappa-B ligand (RANKL), denosumab. IH is a rare cause of hypercalcemia. Physicians should be aware of this condition when seeing patients with restricted physical activity

PDF

___

1. Albright F, Burnett CH, Cope O, Parsons W. Acute atrophy of bone (osteoporosis) simulating hyperparathyroidism. J Clin Endocrinol. 1941;1:711-716.

2. Tori JA, Hill LL. Hypercalcemia in children with spinal cord injury. Arch Phys Med Rehabil. 1978;59(10):443-6.

3. Maynard FM. Immobilization hypercalcemia following spinal cord injury. Arch Phys Med Rehabil. 1986;67(1):41-4.

4. Meythaler JM, Korkor AB, Nanda T, Kumar NA, Fallon M. Immobilization hypercalcemia associated with Landry-Guillain-Barré syndrome. Successful therapy with combined calcitonin and etidronate. Arch Intern Med. 1986;146(8):1567-71.

5. Stewart AF, Adler M, Byers CM, Segre GV, Broadus AE. Calcium homeostasis in immobilization: an example of resorptive hypercalciuria. N Engl J Med. 1982;306(19):1136-40.

6. Benjamin RW, Moats-Staats BM, Calikoglu's A, Savendahl L, Chrysis D. Hypercalcemia in children. Pediatr Endocrinol Rev. 2008;5(3):778-84.

7. Naftchi NE, Viau AT, Sell GH, Lowman EW. Mineral metabolism in spinal cord injury. Arch Phys Med Rehabil. 1980;61(3):139-42.

8. Sato Y, Asoh T, Kaji M, Oizumi K. Beneficial effect of intermittent cyclical etidronate therapy in hemiplegic patients following an acute stroke. J Bone Miner Res. 2000;15(12):2487-94.

9. Bikle DD, Halloran BP. The response of bone to unloading. J Bone Miner Metab. 1999;17(4):233-44.

10. Krieger NS, Sessler NE, Bushinsky DA. Acidosis inhibits osteoblastic and stimulates osteoclastic activity in vitro. Am J Physiol. 1992; 262(3 Pt 2):F442-8.

11. Massagli TL, Cardenas DD. Immobilization hypercalcemia treatment with pamidronate disodium after spinal cord injury. Arch Phys Med Rehabil. 1999;80(9):998-1000.

12. Gopal H, Sklar AH, Sherrard DJ. Symptomatic hypercalcemia of immobilization in a patient with end-stage renal disease. Am J Kidney Dis. 2000;35(5):969-72.

13. Gallacher SJ, Ralston SH, Dryburgh FJ, Logue FC, Allam BF, Boyce BF, Boyle IT. Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate. Postgrad Med J. 1990;66(781):918-22.

14. Khairallah W, Fawaz A, Brown EM, El-Hajj Fuleihan G. Hypercalcemia and diabetes insipidus in a patient previously treated with lithium. Nat Clin Pract Nephrol. 2007;3(7):397-404.

15. Gilchrist NL, Frampton CM, Acland RH, Nicholls MG, March RL, Maguire P, Heard A, Reilly P, Marshall K. Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2007;92(4):1385-90.

16. Valverde P. Pharmacotherapies to manage bone loss-associated diseases: a quest for the perfect benefit-to-risk ratio. Curr Med Chem. 2008;15(3):284-304.

17. Maier JD, Levine SN. Hypercalcemia in the Intensive Care Unit: A Review of Pathophysiology, Diagnosis, and ModernTherapy. J Intensive Care Med. 2013 Oct 15. [Epub ahead of print].

18. Ahmad S, Kuraganti G, Steenkamp D. Hypercalcemic Crisis: A Clinical Review. Am J Med. 2014 Oct 17. pii: S0002-9343(14)00915-2. [Epub ahead of print].

19. Machado CE, Flombaum CD. Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol. 1996;45(3):175-9.

20. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19(2):558-67.

21. Pecherstorfer M, Brenner K, Zojer N. Current management strategies for hypercalcemia. Treat Endocrinol. 2003;2(4):273-92.

22. Leyland-Jones B. Treating cancer-related hypercalcemia with gallium nitrate. J Support Oncol. 2004;2(6):509-16.

23. Yasuda H. RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases. World J Orthop. 2013;4(4):207-17.

24. Booth KA, Hays CI. Using denosumab to treat immobilization hypercalcemia in a post-acute care patient. J Clin Endocrinol Metab. 2014;99(10):3531-5.